Non-small cell lung cancer (NSCLC) accounts for about 80–85% of lung cancer cases in the United States.
This information comes from the American Cancer Society (ACS).
Checkpoint inhibitors are a newer form of therapy that helps the body’s immune system target cancer cells.
Keep reading to learn more about how these drugs prevent cancer cells from growing and spreading to other areas of the body.
Immune checkpoints act as signals to prevent the immune system from attacking healthy cells in the body.
According to the
Checkpoint inhibitors prevent cancer cells from binding to T cells. As a result, the immune system can find and target the cancer cells.
However, these drugs are not without risk.
A person should talk with a doctor about the possible benefits and risks before starting checkpoint inhibitor therapy.
The ACS indicate that there are two main types of checkpoint inhibitor used to treat NSCLC. They are PD-1/PD-L1 inhibitors and CTLA-4 inhibitors.
Each type works by targeting a different protein on the T cell. Both types can help the immune system target cancer cells, and they each have potential side effects.
According to a
However, these inhibitors can also cause severe immune-related adverse reactions. More research into novel PD-1/PD-L1 inhibitors that will produce fewer adverse reactions is vital for safety and efficacy.
The ACS indicate that there are five different types of PD-1/PD-L1 inhibitor available for the treatment of NSCLC. They are:
- nivolumab (Opdivo), PD-1
- pembrolizumab (Keytruda), PD-1
- cemiplimab (Libtayo), PD-1
- atezolizumab (Tecentriq), PD-L1
- durvalumab (Imfinzi), PD-L1
A doctor may prescribe PD-1/PD-L1 medications as a first-line treatment either with or without other therapies. Some are for more advanced cases of lung cancer. A person will receive these medications intravenously every 2, 3, 4, or 6 weeks.
CTLA-4 is another type of protein that a cancer cell may use to evade detection from the immune system.
According to the ACS, there is one CTLA-4 inhibitor for NSCLC. It is called ipilimumab (Yervoy). A person will receive this medication intravenously every 6 weeks.
A doctor may prescribe Yervoy along with Opdivo (for PD-1) with or without chemotherapy. However, they will not give this medication on its own.
Both types of checkpoint inhibitor can cause side effects to occur.
According to the
Factors that affect the severity of side effects include:
- the person’s health before starting the medication
- the type of immune checkpoint inhibitor
- the type of cancer
- the dose
- how advanced the cancer is
The most common side effects can include:
- joint pain
- loss of appetite
Serious side effects can occur as well. According to the ACS, serious side effects occur more often in CTLA-4 therapy than in PD-1/PD-L1 therapy.
Serious side effects include autoimmune reactions and infusion reactions.
Autoimmune reactions occur when the immune system attacks healthy cells in other organs, such as the lungs, liver, or kidneys. This can result in life threatening emergencies.
Infusion reactions are similar to allergic reactions. Symptoms can include chills, fever, difficulty breathing, dizziness, wheezing, and an itchy rash.
A person should talk with a doctor before starting checkpoint inhibitors, as they can cause serious reactions in some people.
Doctors are not able to determine ahead of time if a person will experience side effects. As a result, a person should contact a doctor if they notice any new symptoms.
If symptoms cause a person to experience difficulty breathing or other severe reactions, they need emergency care immediately.
Checkpoint inhibitors are one first-line treatment for NSCLC. There are two main types: PD-1/PD-L1 inhibitors and CTLA-4 inhibitors. Both can help the immune system target and attack cancer cells.
Both can cause side effects, however, so a person should talk with a doctor about the pros and cons of their use. They should also let the doctor know right away if they notice any side effects or severe reactions.